The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.
Jack Alistair SargeantJames A KingThomas YatesEmma L RedmanDanielle H BodicoatSudesna ChatterjeeCharlotte L EdwardsonLaura J GrayBenoit PoulinGhazala WaheedHelen L WallerKamlesh KhuntiScott A WillisJohn P H WildingKamlesh Khunti F MedSciDavid J StenselMelanie Jane DaviesPublished in: Diabetes, obesity & metabolism (2022)
gov; 2015-001594-40, www.EudraCT.ema.europa.eu; ISRCTN82062639, www.ISRCTN.org.